CompletedNot Applicable

Effects of Cornelian Cherry Supplementation in Patients With Metabolic Syndrome

Poland55 participantsStarted 2019-01-17

Plain-language summary

This randomized, double-blind, placebo-controlled, parallel-group study evaluated the effects of six-month oral supplementation with Cornus mas fruit lyophilizate in patients with metabolic syndrome. Participants were assigned to receive either 8 g of Cornus mas fruit lyophilizate once daily or a matching placebo. Ophthalmic assessments included best-corrected visual acuity, slit-lamp examination, dilated fundus examination, applanation tonometry, and Doppler ultrasonography of the ophthalmic, central retinal, and posterior ciliary arteries. Cardiometabolic and biochemical parameters were also assessed at baseline and after 3 and 6 months of supplementation.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: aged between 18 and 70 years, with diagnosed metabolic syndrome (central obesity with a waist circumference of ≥ 94 cm in men and ≥ 80 cm in women) and at least 2 of the following criteria: elevated fasting triglyceride levels of ≥ 1.7 mmol/l, low HDL cholesterol (\<1.03 mmol/l in men and \>1.29 mmol/l in women), elevated blood pressure (systolic ≥130 mmHg and diastolic ≥85 mmHg), and fasting glucose level ≥6.5 mmol/l. The ophthalmological inclusion criteria for patients were as follows: best-corrected visual acuity ≥ 20/40, spherical refraction between -4 and +4 dioptres, and cylindrical correction within the range of ± 3.0 dioptres. Exclusion Criteria: smoking, insulin-dependent diabetes, liver or gastrointestinal diseases, cancer, inflammatory diseases, taking weight-loss or anti-inflammatory medication, pregnancy, breastfeeding, alcohol or drug abuse, the need to follow a medically prescribed diet (other than the diet recommended for metabolic syndrome) . Patients with hypotension, severe circulatory failure or other abnormalities of the vascular endothelium that could affect blood flow to the optic nerve head were also excluded from the study. Patients were excluded from the study if they had undergone eye surgery within 12 months prior to the start of the study. Patients with intraocular diseases (e.g. age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, glaucoma, serious acquired or hereditary eye diseases) or neurologi…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Red Blood Cell Count

Timeframe: Baseline, 3 months, and 6 months

CRP

Timeframe: Baseline, 3 months, and 6 months

lipid profile

Timeframe: Baseline, 3 months, and 6 months

urea level test

Timeframe: Baseline, 3 months, and 6 months

creatinine test

Timeframe: Baseline, 3 months, and 6 months

insulin test

Timeframe: Baseline, 3 months, and 6 months

The OGTT (Oral Glucose Tolerance Test)

Timeframe: Baseline, 3 months, and 6 months

A fibrinogen test

Timeframe: Baseline, 3 months, and 6 months

Trial details

NCT IDNCT07739602

SponsorWroclaw Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-25

View on ClinicalTrials.gov More Metabolic Syndrome trials

Plain-language summary

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Red Blood Cell Count

Timeframe: Baseline, 3 months, and 6 months

CRP

Timeframe: Baseline, 3 months, and 6 months

lipid profile

Timeframe: Baseline, 3 months, and 6 months

urea level test

Timeframe: Baseline, 3 months, and 6 months

creatinine test

Timeframe: Baseline, 3 months, and 6 months

insulin test

Timeframe: Baseline, 3 months, and 6 months

The OGTT (Oral Glucose Tolerance Test)

Timeframe: Baseline, 3 months, and 6 months

A fibrinogen test

Timeframe: Baseline, 3 months, and 6 months